ClearPoint Neuro Announces Full Market Release of SmartFrame OR and ClearPoint PRISM 3T Laser Therapy System
ClearPoint Neuro Announces Full Market Release of SmartFrame OR and ClearPoint PRISM 3T Laser Therapy System
SOLANA BEACH, Calif., June 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announces full market release of its SmartFrame OR platform and ClearPoint Prism Neuro Laser Therapy System at the 2024 Biennial Meeting of the American Society of Stereotactic and Functional Neurosurgery from Saturday, June 1st – Tuesday, June 4th in Nashville.
加利福尼亞州索拉納海灘，2024年6月1日（GLOBE NEWSWIRE）——提供大腦和脊柱精確導航的全球設備、細胞和基因療法支持公司ClearPoint Neuro, Inc.（納斯達克股票代碼：CLPT）（“公司”）今天在美國立體定向學會2024年雙年度會議上宣佈其SmartFrame OR 平台和ClearPoint Prism 神經激光治療系統的全面市場發佈以及6月1日星期六至6月4日星期二在納什維爾舉行的功能性神經外科手術。
"Deep Brain Stimulation (DBS) has been proven to be a safe and effective strategy to manage patients with medically intractable Parkinson's Disease, Essential Tremor, and Dystonia,1" said Dr. Kim Burchiel, Professor of Neurological Surgery at the Oregon Health & Science University. "In its more than 30-year history in the US, this highly effective therapy has been mostly performed in highly specialized neurosurgical centers, which, because of their relative rarity, has resulted in only about 5% of eligible patients being treated.1 The development of the SmartFrame OR is anticipated to be a significant step towards accomplishing the triple aim of achieving excellent outcomes in an accessible and appropriate clinical setting, with broad patient acceptance, because it is expected to allow DBS procedures to be performed in a much larger spectrum of hospitals, by a larger contingent of well-trained neurosurgeons."
俄勒岡健康與科學大學神經外科教授金·伯奇爾博士說：“事實證明，深部腦刺激（DBS）是管理醫學上難以治癒的帕金森氏病、特發性震顫和肌張力障礙患者的安全有效的策略1。”“在美國30多年的歷史中，這種高效療法主要在高度專業化的神經外科中心進行，由於其相對罕見，只有大約5％的符合條件的患者接受了治療。1預計SmartFrame OR的開發將是朝着實現三重目標邁出的重要一步，即在可獲得和適當的臨床環境中獲得良好的療效，獲得患者的廣泛接受，因爲它有望允許星展銀行手術將在更大的頻譜中執行醫院是由一支訓練有素的神經外科醫生組成的。”
"ClearPoint Neuro's new SmartFrame OR solution supports stereotactic precision packaged in an efficient, intuitive, and reliable platform," stated Dr. Andrew Conner, Assistant Professor of Neurosurgery at Oklahoma University. "It has completely changed my DBS practice for the better since its release."
俄克拉荷馬大學神經外科助理教授安德魯·康納博士說：“ClearPoint Neuro的新款SmartFrame手術室解決方案支持立體定向精度，封裝在一個高效、直觀和可靠的平台上。”“自發布以來，它徹底改變了我的星展銀行慣例。”
"This is a truly exciting milestone for ClearPoint, and one that has been years in the making," commented Joe Burnett, President and CEO at ClearPoint Neuro. "We set out to prove that we are one of the most innovative and focused companies in the Neurosurgery space. We are now walking into the premier stereotactic neurosurgical conference able to demonstrate new laser therapy, new operating room navigation, new brain modeling software, new access products and new drug delivery preclinical and clinical trial services. This is meaningful innovation that will ultimately benefit our surgical customers and most importantly, many new patients around the world."
ClearPoint Neuro總裁兼首席執行官喬·伯內特評論說：“對於ClearPoint來說，這確實是一個激動人心的里程碑，而且已經持續了多年。”“我們着手證明我們是神經外科領域最具創新性和專注力的公司之一。我們現在正在進入首屈一指的立體定向神經外科會議，該會議能夠展示新的激光療法、新的手術室導航、新的大腦建模軟件、新的准入產品以及新的藥物遞送臨床前和臨床試驗服務。這是一項有意義的創新，最終將使我們的外科客戶受益，最重要的是，將使世界各地的許多新患者受益。”
At ASSFN, the SmartFrame OR and ClearPoint Prism Neuro Laser Therapy System will be showcased at:
在 ASSFN 上，SmartFrame OR 和 ClearPoint Prism 神經激光治療系統將在以下地點展出：
Special Course 1: Epilepsy Surgery Fundamentals and Challenges on Saturday, June 1st
Special Course 2: Movement Disorder Surgery Fundamentals and Challenges on Saturday, June 1st
Meet the Expert Session: Initial Experience with the SmartFrame OR Platform
特別課程1：6月1日星期六的癲癇手術基礎知識和挑戰
特別課程2：運動障礙手術基礎知識和挑戰（6月1日星期六）
會見專家會議：SmartFrame OR 平台的初步經驗
譯文內容由第三人軟體翻譯。